201 related articles for article (PubMed ID: 19934273)
1. p57KIP2: "Kip"ing the cell under control.
Pateras IS; Apostolopoulou K; Niforou K; Kotsinas A; Gorgoulis VG
Mol Cancer Res; 2009 Dec; 7(12):1902-19. PubMed ID: 19934273
[TBL] [Abstract][Full Text] [Related]
2. p57(Kip2) and cancer: time for a critical appraisal.
Borriello A; Caldarelli I; Bencivenga D; Criscuolo M; Cucciolla V; Tramontano A; Oliva A; Perrotta S; Della Ragione F
Mol Cancer Res; 2011 Oct; 9(10):1269-84. PubMed ID: 21816904
[TBL] [Abstract][Full Text] [Related]
3. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
[TBL] [Abstract][Full Text] [Related]
4. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Puhalla H; Wrba F; Kandioler D; Lehnert M; Huynh A; Gruenberger T; Tamandl D; Filipits M
Anticancer Res; 2007; 27(3B):1679-84. PubMed ID: 17595796
[TBL] [Abstract][Full Text] [Related]
5. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes.
Gosselet FP; Magnaldo T; Culerrier RM; Sarasin A; Ehrhart JC
Cell Signal; 2007 Apr; 19(4):731-9. PubMed ID: 17112701
[TBL] [Abstract][Full Text] [Related]
6. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes.
Curry JL; Richards HW; Huttenbach YT; Medrano EE; Reed JA
J Cutan Pathol; 2009 Feb; 36(2):197-205. PubMed ID: 18647205
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells.
Nakano N; Urasawa K; Takagi Y; Saito T; Kaneta S; Ishikawa S; Higashi H; Tsutsui H; Hatakeyama M; Kitabatake A
Biochem Biophys Res Commun; 2005 Dec; 338(3):1661-7. PubMed ID: 16259944
[TBL] [Abstract][Full Text] [Related]
8. The multiple roles of the cyclin-dependent kinase inhibitory protein p57(KIP2) in cerebral cortical neurogenesis.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Dev Neurobiol; 2012 Jun; 72(6):821-42. PubMed ID: 22076965
[TBL] [Abstract][Full Text] [Related]
9. Contrasting roles of p57(KIP2) and p21(WAF1/CIP1/SDI1) in transplanted human and bovine adrenocortical cells.
Thomas M; Popnikolov NK; Scott C; Smith JR; Hornsby PJ
Exp Cell Res; 2001 May; 266(1):106-13. PubMed ID: 11339829
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Orlow I; Iavarone A; Crider-Miller SJ; Bonilla F; Latres E; Lee MH; Gerald WL; Massagué J; Weissman BE; Cordón-Cardó C
Cancer Res; 1996 Mar; 56(6):1219-21. PubMed ID: 8640801
[TBL] [Abstract][Full Text] [Related]
11. Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Croucher DR; Rickwood D; Tactacan CM; Musgrove EA; Daly RJ
Mol Cell Biol; 2010 Nov; 30(21):5057-70. PubMed ID: 20805359
[TBL] [Abstract][Full Text] [Related]
12. Functional Versatility of the CDK Inhibitor p57
Creff J; Besson A
Front Cell Dev Biol; 2020; 8():584590. PubMed ID: 33117811
[TBL] [Abstract][Full Text] [Related]
13. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
14. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
15. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.
Zohny SF; Baothman OA; El-Shinawi M; Al-Malki AL; Zamzami MA; Choudhry H
Cancer Biomark; 2017; 18(4):413-423. PubMed ID: 28106536
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Chow SE; Wang JS; Lin MR; Lee CL
J Cell Biochem; 2011 Nov; 112(11):3459-68. PubMed ID: 21769918
[TBL] [Abstract][Full Text] [Related]
17. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
Vlachos P; Joseph B
Oncogene; 2009 Nov; 28(47):4175-88. PubMed ID: 19734939
[TBL] [Abstract][Full Text] [Related]
18. Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.
Stampone E; Caldarelli I; Zullo A; Bencivenga D; Mancini FP; Della Ragione F; Borriello A
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614816
[TBL] [Abstract][Full Text] [Related]
19. Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML.
Brakensiek K; Länger F; Kreipe H; Lehmann U
Leuk Res; 2005 Nov; 29(11):1357-60. PubMed ID: 15936816
[TBL] [Abstract][Full Text] [Related]
20. Roles for p21waf1/cip1 and p27kip1 during the adaptation response to massive intestinal resection.
Stehr W; Bernal NP; Erwin CR; Bernabe KQ; Guo J; Warner BW
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G933-41. PubMed ID: 16322092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
